HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Future Use Of Titanium Dioxide In Spray And Powder Cosmetics Hinges On SCCS Review

Executive Summary

As of 5 February, the Scientific Committee on Consumer Safety is evaluating use of titanium dioxide – now officially classified as a Category 2 carcinogen in the EU – in cosmetic products that can expose consumers by way of inhalation. Without a favorable SCCS opinion, the ingredient’s use in those contexts will be banned under Article 15 of the Cosmetics Regulation.

You may also be interested in...



TiO2 Still A California Prop 65 Target; EU Commission Returns To SCCS With New Safety Questions

Titanium dioxide use in cosmetic products is getting another look by the EU’s Scientific Committee on Consumer Safety, with a focus on genotoxicity and exposure via inhalation and oral routes. Stateside, potentially respirable TiO2 continues to be the focus of Prop 65 lawsuits in California.

Common Dietary Supplement Additive Ruled Unsafe By EU Regulator

Titanium dioxide - used as a colorant in many dietary supplements - is no longer considered safe when used as a food additive, says the European Food Safety Authority. The European Commission and EU member states must now decide whether to follow France's lead and ban its use in foods outright. 

Blue Lizard Zinc-Only Sunscreen Sprays With Earth-Friendly Propellent; More Product Launch News

New beauty and personal-care products from Jack Black, Dabble & Dollop, Lady Gaga’s Haus Laboratories, and more.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS149715

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel